
    lack of efficacy
  
['atopic dermatitis']
['placebo', 'zpl389', 'zpl389', 'zpl389', 'zpl389']

        Inclusion Criteria:

          -  Subjects must give a written, signed and dated informed consent

          -  Chronic atopic dermatitis present for at least 1 year before Baseline

          -  Moderate to severe atopic dermatitis defined as per EASI, IGA and BSA.

          -  Documented recent history (within 6 months before the screening visit) of inadequate
             response to treatment with topical medications or for whom topical treatments are
             otherwise medically inadvisable

          -  Candidate for systemic treatment

        Exclusion Criteria:

          -  Any skin disease that would confound the diagnosis or evaluation of atopic dermatitis
             disease activity

          -  Use of other investigational drugs within 5 half-lives of enrollment, or within 30
             days or until the expected pharmacodynamic effect has returned to baseline, whichever
             is longer.

          -  History of hypersensitivity to any of the study drug constituents or to drugs of
             similar chemical classes.

          -  Participation in prior ZPL389 studies
      